Urological cancer, Malmö
111 – 120 of 532
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach
(
- Contribution to journal › Article
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients
(
- Contribution to journal › Article
-
Mark
Robot-assisted nephroureterectomy for upper tract urothelial carcinoma—feasibility and complications : a single center experience
(
- Contribution to journal › Article
-
Mark
Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma—A Prospective Cohort Study
(
- Contribution to journal › Article
-
Mark
Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation
(
- Contribution to journal › Article
-
Mark
EANM-EAU consensus on PSMA PET/CT in respect to radioligand therapy ([177Lu]Lu-PSMA)
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article